Takeda Pharmaceutical Co ADR [TAK] stock is trading at $14.47, down -0.41%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TAK shares have gain 0.70% over the last week, with a monthly amount glided 2.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Takeda Pharmaceutical Co ADR [NYSE: TAK] stock has seen the most recent analyst activity on April 02, 2025, when Morgan Stanley upgraded its rating to an Overweight. Previously, BofA Securities upgraded its rating to Buy on March 16, 2023, and kept the price target unchanged to $20. On July 19, 2022, upgrade upgraded it’s rating to Outperform and revised its price target to $24 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight. JP Morgan downgraded its rating to a Neutral. Cowen started tracking with a Market Perform rating for this stock on November 01, 2019, and assigned it a price target of $19.50. In a note dated August 15, 2019, Daiwa Securities downgraded a Neutral rating on this stock.
Takeda Pharmaceutical Co ADR [TAK] stock has fluctuated between $12.80 and $15.69 over the past year. Takeda Pharmaceutical Co ADR [NYSE: TAK] shares were valued at $14.47 at the most recent close of the market.
Analyzing the TAK fundamentals
Takeda Pharmaceutical Co ADR [NYSE:TAK] reported sales of 29.63B for the trailing twelve months, which represents a drop of -4.25%. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.02 and Total Capital is 0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.42 points at the first support level, and at 14.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.53, and for the 2nd resistance point, it is at 14.59.
Ratios To Look Out For
For context, Takeda Pharmaceutical Co ADR’s Current Ratio is 1.36. Further, the Quick Ratio stands at 0.76, while the Cash Ratio is 0.16. Considering the valuation of this stock, the price to sales ratio is 1.54, the price to book ratio is 0.95 and price to earnings (TTM) ratio is 183.63.
Transactions by insiders
Recent insider trading involved Lauren Rusckowski Duprey, Chief Human Resources Officer, that happened on Dec 09 ’25 when 29619.0 shares were purchased. President, Global Oncology Bus, Teresa Marie Bitetti completed a deal on Dec 05 ’25 to buy 87023.0 shares. Meanwhile, President, Plasma-Derived Ther Giles Richard Platford bought 58421.0 shares on Dec 04 ’25.
